Manufacturer Supply Darunavir Related Products:
Darunavir CAS 206361-99-1
Darunavir Ethanolate CAS 635728-49-3
(2S,3S)-1,2-Epoxy-3-(Boc-Amino)-4-Phenylbutane CAS 98737-29-2
(2R,3S)-1,2-Epoxy-3-(Boc-Amino)-4-Phenylbutane CAS 98760-08-8
(3S)-3-(tert-Butoxycarbonyl)amino-1-Chloro-4-Phenyl-2-Butanone CAS 102123-74-0
| Chemical Name | Darunavir |
| Synonyms | TMC114; UIC-94017 |
| CAS Number | 206361-99-1 |
| CAT Number | RF-API68 |
| Stock Status | In Stock, Production Scale Up to Hundreds of Kilograms |
| Molecular Formula | C27H37N3O7S |
| Molecular Weight | 547.66 |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White or Off-White Crystalline Powder |
| Identification | MS/HNMR HPLC |
| Solubility | Soluble in DMSO, Slightly Soluble in Water |
| Melting Point | 74.0~76.0℃ |
| Identification | 1H NMR |
| Purity / Analysis Method | ≥99.0% (HPLC) |
| Related Substances | |
| Max Single Impurity | ≤0.30% |
| Total Impurities | ≤1.0% |
| Residual Solvents | Ethanol ≤0.30% |
| Loss on Drying | ≤0.50% |
| Residue on Ignition | ≤0.10% |
| Heavy Metals | ≤20ppm |
| Arsenic | ≤1.5ppm |
| Test Standard | Enterprise Standard |
| Usage | Darunavir (CAS 206361-99-1) HIV-1 Protease Inhibitor Anti-HIV |
Package: Bottle, Aluminium foil bag, Cardboard Drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Darunavir (brand name Prezista, formerly known as TMC114) is a protease inhibitor medication used to treat HIV infection. Darunavir is an OARAC recommended treatment option for treatment-naive and treatment-experienced adults and adolescents. Darunavir is a new kind of non peptide anti retroviral protease inhibitors in AIDS therapy. It is first developed by the Johnson pharmaceutical Iceland branch, Tibotec. It is of the highest bioavailability in the 6 protease inhibitors (saquinavir, ritonavirvir, indinavir, naphthalene nelfinavir, amprenavir and ABT378/r). It acts by blocking the formation of new and mature virus particles from the surface of the infected host cells and inhibiting the virus's protease. When the product is used for a long time, it usually can reduce the HIV virus vector in blood, increase the count of CD4 cells, reduce the chance of HIV infection, improve the quality of life and prolong life. It is suitable for adults who are infected with the HIV virus but have no effect on the use of existing antiretroviral drugs. The drug must be combined with the use of low doses of ritonavir or other antiretroviral agents, in order to improve the efficacy. The antiviral activity in vitro can be evaluated by being against acute and chronic infected lymphocytes and lymphocytes in peripheral blood.